nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

Cell Death Modulation by Intravenous Immunoglobulin

verfasst von: Stephan von Gunten, Hans-Uwe Simon

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The induction of cell death in immune cells by naturally occurring antibodies specific for death receptors may present an important antiinflammatory mechanism of intravenous immunoglobulin (IVIG). Conversely, the protection of tissue cells from death receptor-mediated apoptosis by blocking antibodies is thought to contribute to the beneficial effects of IVIG in certain inflammatory disorders such as toxic epidermal necrolysis, also known as Lyell's syndrome. In this review, we focus on recent insights into the role of functional antibodies against Fas, sialic acid-binding immunoglobulin-like lectin (Siglec)-8, and Siglec-9 receptors in IVIG-mediated cell survival or death effects. In addition, we examine a variety of factors in inflammatory disease that may interplay with these cellular events and influence the therapeutic efficacy or potency of IVIG. These involve activation status of the target cell, cytokine microenvironment, pathogenesis and stage of disease, individual genetic determinants, species characteristics, and batch-to-batch variations of IVIG preparations.

Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon LUC, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233–45.CrossRefPubMed

Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513.CrossRefPubMed

von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev. 2008;7:453–6.CrossRef

Simon HU, Späth PJ. IVIG—mechanisms of action. Allergy. 2003;58:543–52.CrossRefPubMed

von Gunten S, Smith D, Cummings R, Riedel S, Miescher S, Schaub A, et al. Intravenous immunoglobulin contains a broad repertoire of anti-carbohydrate antibodies that is not restricted to the IgG2 subclass. J Allergy Clin Immunol. 2009;123:1268–76.CrossRef

Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–55.CrossRefPubMed

Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, et al. IVIg perspective. Autoimmun Rev. 2008;7:440–4.CrossRefPubMed

Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180–92.CrossRefPubMed

Simon HU. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev. 2003;193:101–10.CrossRefPubMed

10.

Simon HU. Regulation of eosinophil and neutrophil apoptosis—similarities and differences. Immunol Rev. 2001;179:156–62.CrossRefPubMed

11.

Sprent J, Tough DF. T cell death and memory. Science. 2001;293:245–8.CrossRefPubMed

12.

von Gunten S, Bochner BS. Expression and function of Siglec-8 in human eosinophils, basophils, and mast cells. In: Pawankar R, Holgate ST, Rosenwasser LJ, editors. Allergy frontiers: classification and pathomechanisms. Tokyo, Japan: Springer; 2009. p. 297–231.

13.

von Gunten S, Simon HU. Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J. 2006;29:601–5.CrossRef

14.

Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–8.CrossRefPubMed

15.

Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med. 2002;8:61–7.CrossRefPubMed

16.

Conus S, Perozzo R, Reinheckel T, Peters C, Scapozza L, Yousefi S, et al. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med. 2008;205:685–98.CrossRefPubMed

17.

Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–7.CrossRefPubMed

18.

Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969–76.CrossRefPubMed

19.

Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–46.CrossRefPubMed

20.

Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–9.CrossRefPubMed

21.

Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–3.CrossRefPubMed

22.

Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781–90.PubMed

23.

Sooryanarayana, Prasad N, Bonnin E, Pashov A, Ben Jilani K, Ameisen JC, et al. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun. 1999;264:896–901.CrossRefPubMed

24.

Altznauer F, von Gunten S, Späth P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol. 2003;112:1185–90.CrossRefPubMed

25.

Reipert BM, Stellamor MT, Poell M, Ilas J, Sasgary M, Reipert S, et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang. 2008;94:334–41.CrossRefPubMed

26.

Crocker PR, Clark EA, Filbin M, Gordon S, Jones Y, Kehrl JH, et al. Siglecs: a family of sialic-acid binding lectins. Glycobiology. 1998;8:v–vi.PubMed

27.

von Gunten S, Bochner BS. Basic and clinical immunology of Siglecs. Ann N Y Acad Sci. 2008;1143:61–82.CrossRef

28.

Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255–66.CrossRefPubMed

29.

Varki A, Angata T. Siglecs—the major subfamily of I-type lectins. Glycobiology. 2006;16:1R–27R.CrossRefPubMed

30.

O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell–mediated disease. Trends Pharmacol Sci. 2009;30:240–8.CrossRefPubMed

31.

Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. PNAS. 2006;103:7765–70.

32.

Varki A. Glycan-based interactions involving vertebrate sialic-acid–recognizing proteins. Nature. 2007;446:1023–9.CrossRefPubMed

33.

von Gunten S, Yousefi S, Seitz M, Jakob SM, Schaffner T, Seger R, et al. Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood. 2005;106:1423–31.CrossRef

34.

Rashmi R, Bode BP, Panesar N, King SB, Rudloff JR, Gartner MR, et al. Siglec-9 and SHP-1 are differentially expressed in neonatal and adult neutrophils. Pediatr Res. 2009;66:266–71.CrossRefPubMed

35.

Guo JP, Nutku E, Yokoi H, Schnaar R, Zimmermann N, Bochner BS. Siglec-8 and Siglec-F: inhibitory receptors on eosinophils and mast cells. Allergy Clin Immunol Int. 2007;19:54–9.CrossRef

36.

Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, Lee HH, et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol. 2008;121:499–505.CrossRefPubMed

37.

Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003;101:5014–20.CrossRefPubMed

38.

Nutku E, Hudson SA, Bochner BS. Mechanism of Siglec-8–induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophys Res Commun. 2005;336:918–24.CrossRefPubMed

39.

Nutku-Bilir E, Hudson SA, Bochner BS. Interleukin-5 priming of human eosinophils alters Siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol. 2008;38:121–4.CrossRefPubMed

40.

Simon HU. Molecules involved in the regulation of eosinophil apoptosis. Chem Immunol Allergy. 2006;91:49–58.CrossRefPubMed

41.

von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, et al. Intravenous immunoglobulin preparations contain anti–Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007;119:1005–11.CrossRef

42.

Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, Simon HU. cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol. 2006;36:1975–84.CrossRefPubMed

43.

Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti–interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–9.CrossRefPubMed

44.

Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117:1292–302.CrossRefPubMed

45.

Takigawa N, Kawata N, Shibayama T, Tada A, Kimura G, Munemasa M, et al. Successful treatment of a patient with severe Churg–Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma. 2005;42:639–41.CrossRefPubMed

46.

Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg–Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92:80–7.CrossRefPubMed

47.

Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004;279:43117–25.CrossRefPubMed

48.

Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol. 2004;173:6841–68419.PubMed

49.

Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood. 2009;113:3333–6.CrossRefPubMed

50.

von Gunten S, Jakob S, Geering B, Takala J, Simon HU. Different patterns of Siglec-9–mediated neutrophil death responses in septic shock. Shock. 2009;32:386–92.CrossRef

51.

von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunological and functional evidence for anti–Siglec-9 autoantibodies in intravenous immunoglobulin (IVIg) preparations. Blood. 2006;108:4255–9.CrossRef

52.

Gelfand EW, Winkelstein J. Are all IGIVs the same? J Allergy Clin Immunol. 2002;110:938.CrossRefPubMed

53.

Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol. 1993;15:120–3.CrossRefPubMed

54.

Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol. 1996;64:175–8.CrossRefPubMed

55.

Berkovitch M, Dolinski G, Tauber T, Aladjem M, Kaplinsky C. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol. 1999;21:411–5.CrossRefPubMed

56.

Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol. 2005;27:145–7.CrossRefPubMed

57.

Matsuda M, Hosoda W, Sekijima Y, Hoshi K, Hashimoto T, Itoh S, et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol. 2003;26:306–11.CrossRefPubMed

58.

Buenz EJ, Howe CL. Appropriate use of intravenous immunoglobulin in neonatal neutropenia. J Perinatol. 2007;27:196–7.CrossRefPubMed

59.

Khan S, Dore PC, Sewell WAC. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease. Pediatr Allergy Immunol. 2008;19:186–7.CrossRefPubMed

Titel: Cell Death Modulation by Intravenous Immunoglobulin
verfasst von: Stephan von Gunten
Hans-Uwe Simon
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9411-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cell Death Modulation by Intravenous Immunoglobulin

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

Method of Identifying Natural Antibodies for Remyelination

Immunoglobulin G: A Potential Treatment to Attenuate Neuroinflammation Following Spinal Cord Injury

Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy

Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells

Natural IgM Antibodies Against Oxidation-Specific Epitopes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin